Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
m |
||
| Line 12: | Line 12: | ||
*2021-03-10: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' | *2021-03-10: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | *2017-08-24: Initial authorization | + | *2017-08-24: Initial authorization for first line treatment of adult patients with advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]]. ''(Based on TIVO-1)'' |
| + | *2017-08-24: Initial authorization for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced [[renal cell carcinoma|RCC]]. ''(Based on TIVO-1)'' | ||
| + | |||
==Also known as== | ==Also known as== | ||
*'''Code name:''' AV-951 | *'''Code name:''' AV-951 | ||
Revision as of 13:07, 16 September 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established (work in progress)
Patient drug information
History of changes in FDA indication
- 2021-03-10: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
History of changes in EMA indication
- 2017-08-24: Initial authorization for first line treatment of adult patients with advanced renal cell carcinoma (RCC). (Based on TIVO-1)
- 2017-08-24: Initial authorization for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. (Based on TIVO-1)
Also known as
- Code name: AV-951
- Brand name: Fotivda